+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Cancer Drugs Market by Drug Type, Mechanism Of Action, Treatment Line, Administration Route, Distribution Channel, End User - Global Forecast to 2030- Product Image
Liver Cancer Drugs Market by Drug Type, Mechanism Of Action, Treatment Line, Administration Route, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Liver Cancer Drugs Market by Drug Type, Mechanism Of Action, Treatment Line, Administration Route, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896742
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Liver Cancer Drugs Market is undergoing substantial transformation as innovation, regulatory dynamics, and evolving clinical practices intersect. Senior decision-makers now face a landscape shaped by precision medicine and integrated care, pushing organizations to reimagine strategy, partnerships, and operational execution across all regions and segments.

Market Snapshot: Liver Cancer Drugs Market Overview

The Liver Cancer Drugs Market grew from USD 987.60 million in 2024 to USD 1.12 billion in 2025. It is expected to continue growing at a CAGR of 14.08%, reaching USD 2.17 billion by 2030. Key drivers include the increased adoption of immunotherapies and targeted treatments, as well as expanded clinical options for hepatocellular carcinoma. The competitive environment is intensifying as pharmaceutical leaders and emerging biotech companies focus on portfolio expansion and strategic partnerships.

Scope & Segmentation

  • Drug Types: Chemotherapy, Immunotherapy, Targeted Therapy
  • Mechanism of Action: Immune checkpoint inhibitors (CTLA-4, PD-L1, PD-1), mTOR inhibitors, tyrosine kinase inhibitors (multi-kinase, selective kinase variants), VEGF inhibitors
  • Treatment Lines: First-line, second-line, and third-line therapies and beyond
  • Administration Routes: Intravenous, oral, subcutaneous
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy
  • End Users: Home care, hospitals, specialty clinics
  • Regional Scope: Americas (with a focus on the United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East, and Africa (including the United Kingdom, Germany, France, and others); Asia-Pacific (including China, India, Japan, Australia, South Korea, and Southeast Asia markets)
  • Leading Companies: Bayer AG, Eisai Co., Ltd., Bristol-Myers Squibb Company, Merck & Co., F. Hoffmann-La Roche Ltd, Ipsen S.A., AstraZeneca plc, Exelixis, Inc.

Key Takeaways for Decision-Makers

  • Precision approaches and combination regimens are redefining the treatment landscape, enabling tailored care for diverse molecular profiles.
  • Innovation in drug formulations, including subcutaneous and oral therapies, is expanding options for at-home care and operational flexibility for healthcare providers.
  • Integration of digital health platforms enhances real-time monitoring and supports more agile, adaptive dosing decisions in clinical settings.
  • Strategic alliances between biotechnology firms and major pharma accelerate product development and market introduction, while enhancing value demonstration through real-world evidence initiatives.
  • Market access is increasingly shaped by national regulatory frameworks, payer negotiations, and local supply chain capabilities, requiring adaptive commercial strategies.

Tariff Impact on the Liver Cancer Drugs Market

Changes in US tariff policy on oncology drug components are prompting manufacturers to review supply chain models. Companies are investing in domestic manufacturing and diversifying sourcing to ensure continuity. These adjustments have intensified cost pressures and prompted more value-based negotiations between suppliers and payers, with increased focus on biosimilar and generic adoption in some markets.

Methodology & Data Sources

This report is based on a hybrid methodology that combines primary interviews with industry experts across oncology, regulatory authorities, and payers, plus secondary research from peer-reviewed journals, agency publications, financial disclosures, and healthcare databases. Findings are triangulated for accuracy, with iterative validation and cross-functional peer review ensuring relevance for stakeholders at all levels.

Liver Cancer Drugs Market: Why This Report Matters

  • Delivers actionable insights on evolving clinical approaches, enabling stakeholders to optimize commercial, regulatory, and R&D strategies.
  • Clarifies regional variations in market access, supporting tailored go-to-market strategies and competitive positioning efforts across global regions.

Conclusion

Liver cancer drug development is becoming increasingly specialized, with new modalities, adaptive supply chains, and evolving payer requirements shaping success. This research guides senior leaders to make informed investment and operational decisions that align with the market’s complex trajectory.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Liver Cancer Drugs Market, by Drug Type
8.1. Introduction
8.2. Chemotherapy
8.3. Immunotherapy
8.4. Targeted Therapy
9. Liver Cancer Drugs Market, by Mechanism Of Action
9.1. Introduction
9.2. Immune Checkpoint Inhibitors
9.2.1. Ctla4 Inhibitors
9.2.2. Pd L1 Inhibitors
9.2.3. Pd1 Inhibitors
9.3. Mtor Inhibitors
9.4. Tyrosine Kinase Inhibitors
9.4.1. Multi Kinase Inhibitors
9.4.2. Selective Kinase Inhibitors
9.5. Vegf Inhibitors
10. Liver Cancer Drugs Market, by Treatment Line
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line And Beyond
11. Liver Cancer Drugs Market, by Administration Route
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Liver Cancer Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Liver Cancer Drugs Market, by End User
13.1. Introduction
13.2. Home Care
13.3. Hospital
13.4. Specialty Clinic
14. Americas Liver Cancer Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Liver Cancer Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Liver Cancer Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Bayer AG
17.3.2. Eisai Co., Ltd.
17.3.3. Bristol-Myers Squibb Company
17.3.4. Merck & Co., Inc.
17.3.5. F. Hoffmann-La Roche Ltd
17.3.6. Ipsen S.A.
17.3.7. AstraZeneca plc
17.3.8. Exelixis, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. LIVER CANCER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. LIVER CANCER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. LIVER CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. LIVER CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CTLA4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY PD L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY PD1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MULTI KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SELECTIVE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 58. CANADA LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 59. CANADA LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. CANADA LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 61. CANADA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 62. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. CANADA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 107. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 110. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 111. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 115. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 118. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 130. ITALY LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 131. ITALY LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 132. ITALY LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. ITALY LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 134. ITALY LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 135. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. ITALY LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 138. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 139. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 142. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 143. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 170. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 171. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 174. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 175. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. QATAR LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 186. QATAR LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 187. QATAR LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 188. QATAR LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. QATAR LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 190. QATAR LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 191. QATAR LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. QATAR LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 194. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 195. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 198. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 199. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 218. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 219. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 221. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 222. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 223. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 226. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 230. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 231. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 242. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 243. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 246. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 247. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. POLAND LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 250. POLAND LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 251. POLAND LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 252. POLAND LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 253. POLAND LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 254. POLAND LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 255. POLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. POLAND LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 274. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 275. CHINA LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 276. CHINA LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 277. CHINA LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 278. CHINA LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 279. CHINA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 280. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. CHINA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. INDIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 283. INDIA LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 284. INDIA LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 285. INDIA LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 286. INDIA LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 287. INDIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 288. INDIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. INDIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 291. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 292. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 294. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 295. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 296. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 323. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 324. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 325. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 326. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 327. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 328. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 329. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES LIVER CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES LIVER CANCER DRUGS MA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Liver Cancer Drugs market report include:
  • Bayer AG
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Ipsen S.A.
  • AstraZeneca plc
  • Exelixis, Inc.

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.12 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.17 Billion
Compound Annual Growth Rate14.0%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028 - Product Image

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028

  • Report
  • 88 Pages
  • United States
From
Liver Cancer Market Report 2025 - Product Image

Liver Cancer Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Unresectable Hepatocellular Carcinoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Unresectable Hepatocellular Carcinoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 129 Pages
  • Global
From
Hepatic Tumor - Pipeline Insight, 2025 - Product Image

Hepatic Tumor - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Liver Cancer Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application - Product Image

Liver Cancer Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

  • Report
  • 87 Pages
  • Global
From

About the Liver Cancer Drugs Market

The Liver Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat liver cancer. These drugs are used to reduce the size of tumors, reduce symptoms, and improve the quality of life for those affected by the disease. Commonly used drugs include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy is a type of drug that works by killing cancer cells. Targeted therapy is a type of drug that works by targeting specific molecules in cancer cells. Immunotherapy is a type of drug that works by stimulating the body's own immune system to fight cancer. The Liver Cancer Drugs market is highly competitive, with many companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly developing new drugs and treatments to improve the quality of life for those affected by liver cancer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.